Quantcast

Abiomed to Showcase Impella(R) 2.5 Heart Recovery Device at TCT 2008

October 9, 2008

– Investor and Analyst Meeting on October 13 from 5:30 – 6:30 p.m.

— Customer Symposium Featuring Leading Clinician Presentations on October 13 from 7:00 – 9:30 p.m.

— Daily Live Broadcasts of Impella Procedures

Abiomed

Aimee Maillett, 978-646-1553

Public Relations Specialist

amaillett@abiomed.com

Abiomed Inc. (NASDAQ: ABMD) today announced its schedule of events at the Cardiovascular Research Foundation’s (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from October 13 to October 17, in Washington, D.C.

On Monday, October 13, from 5:30 to 6:30 p.m., Abiomed will host an investor and analyst meeting, open to all attendees, providing a 30-minute presentation on Abiomed, with a 30-minute question and answer forum. Following the meeting from 7:00 to 9:30 p.m., will be an invitation-only reception and customer symposium that will focus on Impella 2.5 and feature leading clinical presentations.

At TCT booth #835, Abiomed will broadcast daily live feeds of Impella cases. Potential live cases from participating hospitals may include Columbia University Medical Center, Emory University Hospital, and others. The U.S. Food and Drug Administration (FDA) limits U.S. trial hospitals to two live cases each, therefore the live cases will be announced as they occur based on patient status at each hospital. The company will also conduct daily booth demonstrations and hands-on simulations of its heart recovery platforms, including Impella; Simpella Simulator; iPulseTM Combination Console Platform for Abiomed’s intra-aortic balloon; BVS5000(R) Blood Pump; and AB5000TMCirculatory Support System.

“We believe Impella 2.5 will introduce a new standard of care in the cath lab. With its recent 510(k) clearance in the U.S., Impella continues to generate interest and momentum from leading cardiac hospitals and clinicians,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed, Inc. “We are eager to use this TCT conference as the launch pad for our heart recovery technologies.”

In June 2008, the Impella 2.5 received 510(k) clearance from the FDA for partial circulatory support for periods up to six hours and is already commercially available in over 100 leading U.S. cardiac hospitals. Abiomed is also currently conducting two U.S. pivotal studies comparing the Impella 2.5 to the IABP (Protect II for high- risk percutaneous coronary intervention, or PCI; and Recover II for acute myocardial infarction, AMI or heart attack). There are an estimated 60,000 annual high-risk PCI patients and 100,000 AMI anterior infarct patients annually in the United States.

The Impella 2.5 is the world’s smallest heart pump and is inserted percutaneously in the cath lab via the femoral artery into the left ventricle. Up to 2.5 liters of blood per minute is delivered by the pump from the left ventricle into the ascending aorta, providing the heart with active support in critical situations. Now approved in more than 40 countries, including in Europe under the CE Mark, Impella 2.5 has been used to treat over 1,500 patients outside the U.S. and has been the subject of more than 50 peer-reviewed publications.

In addition, the Abiomed booth will feature physicians presenting challenging cases using Impella 2.5. The presentations will occur daily, from October 14 – 16 at 9:30 a.m., 11:30 a.m., 1:30 p.m., and 3:30 p.m., followed by an Abiomed presentation on U.S. reimbursement. Furthermore, the booth will include a cath lab simulator to provide education and training for physicians and demonstrate the ease of placing the Impella 2.5 catheter.

ABIOMED SCHEDULE OF TCT 2008 EVENTS:

MONDAY, OCTOBER 13

INVESTOR AND ANALYST MEETING

Monday, October 13

Constitution Ballroom at the Grand Hyatt Washington

5:30 – 6:30 p.m.

Michael R. Minogue, Chairman, Chief Executive Officer and President; David Weber, Ph.D., Chief Operating Officer; and Karim Benali, M.D., Chief Medical Officer, will host an investor and analyst meeting, providing a 30-minute overview of the Impella 2.5 and details on the schedule of other Abiomed events at TCT 2008 including live cases, presentations and abstracts. Following the prepared remarks by Abiomed management, will be a 30-minute forum for questions and open discussion.

SYMPOSIUM AND CLINICAL PRESENTATIONS

Monday, October 13

Constitution Ballroom at the Grand Hyatt Washington

7:00 – 8:00 p.m. – Cocktail reception

8:00 – 9:30 p.m. – Symposium and clinical presentations

Abiomed will sponsor an invitation-only TCT symposium entitled, “Introducing Impella 2.5: A New Era in the Cardiac Catheterization Lab,” chaired by Dr. Jeffrey J. Popma, Director Invasive Cardiovascular Services, Caritas St. Elizabeth’s Medical Center and Associate Professor of Medicine, Harvard Medical School, in the Constitution Ballroom of the Grand Hyatt Washington.

SYMPOSIUM TOPICS, SPEAKERS AND PANEL WILL INCLUDE:

Welcome and Introduction, Jeffrey J. Pompa, M.D., Charitas St. Elizabeth’s Medical Center

“Circulatory Support in the Cath Lab: Is There a New Direction?” Roxana Mehran, M.D., New York-Presbyterian/Columbia University Medical Center

“Impella 2.5: From Anecdotal to Evidence Based Medicine,” William O’Neill, M.D., Executive Dean for Clinical Affairs, University of Miami Miller School of Medicine

“Impella Applications in Clinical Trials and Beyond,” Raed Aqel, M.D., Veterans Administrative Hospital, Birmingham; University of Alabama Medical Center

Panel Discussion will include: Karim Benali, M.D., Chief Medical Officer, Abiomed; Jose P.S. Henriques, M.D., Ph.D., Academic Medical Center, University of Amsterdam; Brijeshwar Maini, M.D., FACC, Co- Chair, Cardiovascular Research, Pinnacle Health, Harrisburg, PA

WORKSHOP: INTERVENTIONAL STRATEGIES AND ADJUNCT PHARMACOLOGY IN ACS AND AMI, PART II: ACUTE MYOCARDIAL INFARCTION

Session IV: Quality Measures and Regional Network Approaches

Monday, October 13

Walter E. Washington Convention Center, Room 147AB

5:04 – 5:14 p.m. – William O’Neill, M.D., Executive Dean for Clinical Affairs, University of Miami Miller School of Medicine, will present “Can Hemodynamic Support Reduce Infarct Size and Improve Clinical Outcomes? From IABP to Cardiac Assist and Impella”

TUESDAY, OCTOBER 14

BOOTH PRESENTATIONS ON IMPELLA 2.5 CASES

Tuesday, October 14

Abiomed Booth #835

9:30 – 10:00 a.m. – Neeraj Jolly, M.D., University of Chicago Medical Center

1:30 – 2:00 p.m. – Raed Aqel, M.D., Veterans Administration Hospital, Birmingham; University of Alabama Medical Center

3:30 – 4:00 p.m. – Suresh Mulukutla, M.D., University of Pittsburgh Medical Center

WORKSHOP: DEVICE-BASED APPROACHES FOR HEART FAILURE I: THE CHF DEVICE LANDSCAPE

Session II: Left Ventricular Remodeling

Tuesday, October 14

Walter E. Washington Convention Center, Room 147AB

9:30 – 9:45 a.m. – Mark B. Anderson, M.D., FACS, Robert Wood Johnson University Hospital, will present “Does Short-Term Ventricular Support for Cardiogenic Shock Result in Ventricular Recovery?”

ABSTRACT PRESENTATION

Tuesday, October 14

Walter E. Washington Convention Center, Room 147AB

11:30 – 11:45 a.m. – William O’Neill, M.D., Executive Dean for Clinical Affairs, University of Miami Miller School of Medicine, will present “Protect II: A prospective, multi-center, randomized controlled trial investigating the use of the Impella 2.5 versus intra-aortic balloon pump in patients undergoing non-emergent high- risk PCI”

AFTERNOON SESSIONS: DEVICE-BASED APPROACHES FOR HEART FAILURE II: EMERGING INTERVENTIONAL TECHNOLOGIES

Session I: Acute Support Devices

Tuesday, October 14

Walter E. Washington Convention Center, Room 151AB

2:27 – 2:36 p.m. – Jose P.S. Henriques, M.D., Ph.D, Academic Medical Center in Amsterdam, Netherlands, will present “Impella 2.5 for Reduction of Infarct Size in AMI”

2:36 – 2:45 p.m. – Simon R. Dixon, M.B., Ch.B, William Beaumont Hospital, will present “Impella 2.5 for High Risk PCI”

2:45 – 2:54 p.m. – Bartley Griffith, M.D., University of Maryland, will present “Impella 5.0 for Cardiogenic Shock”

IMPELLA 2.5 HANDS-ON SIMULATIONS

Ongoing, daily simulations of Impella 2.5 at Abiomed Booth #835

LIVE BROADCASTS OF IMPELLA 2.5 CASES

From the Main Theater, Coronary Theater and Structural Heart Theater

Also occurring daily via live feeds at Abiomed Booth #835

9:00 a.m. – 12:00 p.m.

2:00 p.m. – 5:00 p.m.

WEDNESDAY, OCTOBER 15

BOOTH PRESENTATIONS ON IMPELLA 2.5 CASES

Wednesday, October 15

Abiomed Booth #835

9:30 – 10:00 a.m. – Srihari Naidu, M.D., Director of Cardiac Catherization Center, Winthrop University Hospital

11:30 a.m. – 12:00 p.m. – Srihari Naidu, M.D., Director of Cardiac Catherization Center, Winthrop University Hospital

1:30 – 2:00 p.m. – Cyril Nathaniel, M.D., Laurel Cardiology PC, Johnstown, PA

3:30 – 4:00 p.m. – Brijeshwar Maini, M.D., FACC, Co-Chair, Cardiovascular Research, Pinnacle Health, Harrisburg, PA

IMPELLA 2.5 HANDS-ON SIMULATIONS

Ongoing, daily simulations of Impella 2.5 at Abiomed Booth #835

LIVE BROADCASTS OF IMPELLA 2.5 CASES

From the Main Theater, Coronary Theater and Structural Heart Theater

Also occurring daily via live feeds at Abiomed Booth #835

9:00 a.m. – 12:00 p.m.

2:00 p.m. – 5:00 p.m.

THURSDAY, OCTOBER 16

BOOTH PRESENTATIONS ON IMPELLA 2.5 CASES

Thursday, October 16

Abiomed Booth #835

9:30 – 10:30 a.m. – Jeffrey J. Pompa, M.D., Charitas St. Elizabeth’s Medical Center

11:30 a.m. – 12:00 p.m. – Daniel H. Raess, M.D., F.A.C.C., F.A.C.S., Medical Director, Abiomed

1:30 – 2:00 p.m. – Gwen Mayes, JD, MMSc, Director, Government Relations & Reimbursement, Abiomed

3:30 – 4:00 p.m. – Brijeshwar Maini, M.D., FACC, Co-Chair, Cardiovascular Research, Pinnacle Health, Harrisburg, PA

IMPELLA 2.5 HANDS-ON SIMULATIONS

Ongoing, daily simulations of Impella 2.5 at Abiomed Booth #835

LIVE BROADCASTS OF IMPELLA 2.5 CASES

From the Main Theater, Coronary Theater and Structural Heart Theater

Also occurring daily via live feeds at Abiomed Booth #835

9:00 a.m. – 12:00 p.m.

2:00 p.m. – 5:00 p.m.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed, Impella, iPulse, BVS5000, AB5000 and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.

(c) 2008 BUSINESS WIRE. Provided by ProQuest LLC. All rights Reserved.




comments powered by Disqus